JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jun 1, 2024 to Dec 1, 2024v4
  3. Primary completion date: Jun 1, 2022 to Jun 1, 2024
    • Start date: Jun 1, 2021 to Jun 1, 2023
    • Study completion date: Jun 1, 2023 to Jun 1, 2025
    v3
  4. Study arms: 0 to 1v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Trial Details
NCT Number NCT04951947
Lead Sponsor Hunan Province Tumor Hospital
Conditions
(from sponsor)		 Small-cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov